Identifying Breast Cancer Subtypes Associated With Late Recurrence
According to researchers, ER-positive/HER2-negative breast cancers with high associated risks of late recurrence are enriched in therapeutically targetable genes.
Breast Cancer
Trazimera, a Biosimilar to Herceptin, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp; Pfizer), a biosimilar to Herceptin (trastuzumab; Genentech).
First Cancer Immunotherapy Regimen Approved for Breast Cancer Treatment
The Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (atezolizumab; Genentech) in combination with Abraxane.
Fixed-Dose Trastuzumab in Early-Stage HER2-Positive Breast Cancer: Unanswered Questions
A study of patients with HER2-positive early-stage breast cancer receiving fixed doses of trastuzumab found that 67% and 38% of patients were underdosed in the loading and maintenance settings, respectively.
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Herceptin Hylecta Approved for the Treatment of HER2-Overexpressing Breast Cancer
The Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for the treatment of HER2-overexpressing breast cancer.
Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cancer Topics, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Endocrine Cancer, Gastrointestinal Cancers, General Oncology, Gynecologic Cancer, Head and Neck Cancer, Hematologic Cancers, Lung Cancer, Lymphoma, Multiple Myeloma, Pancreatic Cancer, Pediatric Cancer, Prostate Cancer, Renal Cell Carcinoma, Sarcoma, Skin Cancer, Urologic Cancers
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%…
Phthalates and Postmenopausal Breast Cancer
Phthalate biomarker concentrations did not result in an increased risk of developing invasive breast cancer, according to results from a prospective subgroup analysis of women enrolled in the Women’s Health Initiative (WHI).1 Although the study authors didn’t observe a large increase in invasive breast cancer risk as concentrations of phthalate biomarkers increased, they also “weren’t able…
Tumor Hypoxia and Breast Cancer Risk
A well-known means to differentiate between normal and malignant tumors is tissue hypoxia, and a recent study confirmed “extensive intertumor- and intratumor-type heterogeneity in tumor hypoxia” in 8006 tumors across 19 tumor types.The study authors noted “subsets of patients with a range of solid tumors with genetic instability may benefit from hypoxia-targeting therapy.”For community oncologists, study…
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
Next post in General Oncology
